Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Behav Brain Funct ; 9: 27, 2013 Jul 19.
Artigo em Inglês | MEDLINE | ID: mdl-23866300

RESUMO

BACKGROUND: In contrast to olanzapine, ziprasidone has been reported to cause minimal or no weight gain. This study aimed to compare the effects of ziprasidone and olanzapine on weight, body composition, appetite, resting energy expenditure, substrate oxidation, and metabolic parameters in adults with schizophrenia or other psychotic disorders. METHODS: Twenty adults with schizophrenia or other psychotic disorders were randomized 1:1 to ziprasidone 20-160 mg/day or olanzapine 5-20 mg/day for 12 weeks. The mean doses during the 12-week study period were 109(range: 65-140) mg/day for ziprasidone and 11.6(range: 8.2-15.5) mg/day for olanzapine. Body weight, appetite, body composition, resting energy expenditure, and metabolic parameters were measured before and after drug treatment. Outcome measurements before and after medication were compared, and ziprasidone- and olanzapine-treated patients were compared. RESULTS: After 12 weeks, olanzapine-treated patients showed significant weight gain, particularly fat gain, with increased low density lipoprotein-cholesterol and decreased high density lipoprotein-cholesterol concentrations. In contrast, ziprasidone-treated patients showed no significant weight gain with increased high density lipoprotein-cholesterol concentration. CONCLUSIONS: Ziprasidone was associated with a lower propensity for weight gain and central fat deposition than olanzapine. Studies in larger patient samples are required to confirm these results.


Assuntos
Antipsicóticos/farmacologia , Benzodiazepinas/efeitos adversos , Benzodiazepinas/farmacologia , Composição Corporal/efeitos dos fármacos , HDL-Colesterol/efeitos dos fármacos , LDL-Colesterol/efeitos dos fármacos , Metabolismo Energético/efeitos dos fármacos , Piperazinas/efeitos adversos , Piperazinas/farmacologia , Tiazóis/efeitos adversos , Tiazóis/farmacologia , Adolescente , Adulto , Idoso , Antipsicóticos/efeitos adversos , Apetite/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Olanzapina , Projetos Piloto , Transtornos Psicóticos/tratamento farmacológico , Esquizofrenia/tratamento farmacológico , Aumento de Peso , Adulto Jovem
2.
Behav Brain Funct ; 9: 45, 2013 Dec 05.
Artigo em Inglês | MEDLINE | ID: mdl-24308827

RESUMO

BACKGROUND: Previous research on serum total cholesterol and suicidality has yielded conflicting results. Several studies have reported a link between low serum total cholesterol and suicidality, whereas others have failed to replicate these findings, particularly in patients with major affective disorders. These discordant findings may reflect the fact that studies often do not distinguish between patients with bipolar and unipolar depression; moreover, definitions and classification schemes for suicide attempts in the literature vary widely. METHODS: Subjects were patients with one of the three major psychiatric disorders commonly associated with suicide: schizophrenia, bipolar affective disorder, and major depressive disorder (MDD). We compared serum lipid levels in patients who died by suicide (82 schizophrenia, 23 bipolar affective disorder, and 67 MDD) and non-suicide controls (200 schizophrenia, 49 bipolar affective disorder, and 175 MDD). RESULTS: Serum lipid profiles did not differ between patients who died by suicide and control patients in any diagnostic group. CONCLUSIONS: Our results do not support the use of biological indicators such as serum total cholesterol to predict suicide risk among patients with a major psychiatric disorder.


Assuntos
Transtorno Bipolar/sangue , Colesterol/sangue , Transtorno Depressivo Maior/sangue , Esquizofrenia/sangue , Suicídio/psicologia , Adulto , Transtorno Bipolar/psicologia , Transtorno Depressivo Maior/psicologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Psicologia do Esquizofrênico
3.
Psychiatry Investig ; 13(2): 184-9, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-27081378

RESUMO

OBJECTIVE: Lethality of the chosen method during a suicide attempt is a strong risk factor for completion of suicide. We examined whether annual changes in the pattern of suicide methods is related to annual changes in suicide rates among older adults in South Korea and Japan. METHODS: We analyzed annual the World Health Organization data on rates and methods of suicide from 2000 to 2011 in South Korea and Japan. RESULTS: For Korean older adults, there was a significant positive correlation between suicide rate and the rate of hanging or the rate of jumping, and a significant negative correlation between suicide rate and the rate of poisoning. Among older adults in Japan, annual changes in the suicide rate and the pattern of suicide methods were less conspicuous, and no correlation was found between them. CONCLUSION: The results of the present study suggest that the increasing use of lethal suicide methods has contributed to the rise in suicide rates among older adults in South Korea. Targeted efforts to reduce the social acceptability and accessibility of lethal suicide methods might lead to lower suicide rate among older adults in South Korea.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA